Previous 10 | Next 10 |
Rockwell Medical press release ( NASDAQ: RMTI ): Q3 GAAP EPS of -$0.40 beats by $0.08 . Revenue of $18.69M (+16.8% Y/Y) misses by $0.68M . “In light of a very challenging macroeconomic environment, we are pleased with our performance for the third quarte...
Rockwell is restructuring its business in the short-term to drive revenue and expansion opportunities in the growing hemodialysis market and through international pharmaceutical sales By making this strategic shift, Rockwell expects to achieve profitability in 2024...
Rockwell Medical ( NASDAQ: RMTI ) is scheduled to announce Q3 earnings results on Monday, November 14th, before market open. The consensus EPS Estimate is -$0.37 and the consensus Revenue Estimate is $19.37M (+21.1% Y/Y). For further details see: Rockwell Medical...
Rockwell Medical ( NASDAQ: RMTI ) said it is reacquiring distribution rights to its hemodialysis concentrates products from Baxter ( NYSE: BAX ) and agreed to terminate the exclusive distribution agreement signed in October 2014. The company added that the excl...
Expects to be Profitable in 2024 Rockwell Medical, Inc. (“Rockwell” or the “Company”) (Nasdaq: RMTI), a commercial healthcare company focused on providing life-sustaining products for patients suffering from blood disorders and diseases associ...
Rockwell Medical, Inc. (Nasdaq:RMTI), a commercial healthcare company focused on providing life-sustaining products for patients suffering from blood disorders and diseases associated with the kidney, today announced that it will release its financial results for the third quarter ended...
Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a commercial healthcare company focused on providing life-sustaining products for patients suffering from blood disorders and diseases associated with the kidney, today announced tha...
Rockwell Medical, Inc. (Nasdaq: RMTI), a commercial healthcare company focused on providing life-sustaining products for patients suffering from blood disorders and diseases associated with the kidney, today announced that Heather Hunter has joined the Company as SVP, Chief Corporate Af...
Rockwell Medical ( NASDAQ: RMTI ) has risen 7% after the company posted better-than-expected results, helped by strong sales of blood disorder drugs. Rockwell reported Q2 loss of $0.56, that beat by $0.25, while revenue rose 23% Y/Y to $18.68M, which beat ...
Rockwell Medical, Inc. (RMTI) Q2 2022 Earnings Conference Call August 15, 2022, 08:00 ET Company Participants Heather Hunter - SVP & Chief Affairs Officer Mark Strobeck - President, CEO & Director Russell Skibsted - EVP, CFO & Chief Business Officer ...
News, Short Squeeze, Breakout and More Instantly...
Rockwell Medical Inc. Company Name:
RMTI Stock Symbol:
NASDAQ Market:
Rockwell Medical Inc. Website:
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, announced that the Company's President and Chief Executive Officer, Dr. Mark Strobeck ...
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the second ...
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that Tim Chole was promoted to Chief Commercial Officer, reporting to the ...